Increased Serum Levels of sCD14 and sCD163 Indicate a Preponderant Role for Monocytes in COVID-19 Immunopathology
BackgroundEmerging evidence indicates a potential role for monocytes in COVID-19 immunopathology. We investigated two soluble markers of monocyte activation, sCD14 and sCD163, in COVID-19 patients, with the aim of characterizing their potential role in monocyte-macrophage disease immunopathology. To...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2020-09-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fimmu.2020.560381/full |
| _version_ | 1818279732746125312 |
|---|---|
| author | Jose Gómez-Rial Jose Gómez-Rial Maria José Currás-Tuala Irene Rivero-Calle Irene Rivero-Calle Alberto Gómez-Carballa Alberto Gómez-Carballa Miriam Cebey-López Carmen Rodríguez-Tenreiro Ana Dacosta-Urbieta Ana Dacosta-Urbieta Carmen Rivero-Velasco Nuria Rodríguez-Núñez Rocio Trastoy-Pena Javier Rodríguez-García Antonio Salas Antonio Salas Federico Martinón-Torres Federico Martinón-Torres |
| author_facet | Jose Gómez-Rial Jose Gómez-Rial Maria José Currás-Tuala Irene Rivero-Calle Irene Rivero-Calle Alberto Gómez-Carballa Alberto Gómez-Carballa Miriam Cebey-López Carmen Rodríguez-Tenreiro Ana Dacosta-Urbieta Ana Dacosta-Urbieta Carmen Rivero-Velasco Nuria Rodríguez-Núñez Rocio Trastoy-Pena Javier Rodríguez-García Antonio Salas Antonio Salas Federico Martinón-Torres Federico Martinón-Torres |
| author_sort | Jose Gómez-Rial |
| collection | DOAJ |
| description | BackgroundEmerging evidence indicates a potential role for monocytes in COVID-19 immunopathology. We investigated two soluble markers of monocyte activation, sCD14 and sCD163, in COVID-19 patients, with the aim of characterizing their potential role in monocyte-macrophage disease immunopathology. To the best of our knowledge, this is the first study of its kind.MethodsFifty-nine SARS-Cov-2 positive hospitalized patients, classified according to ICU or non-ICU admission requirement, were prospectively recruited and analyzed by ELISA for levels of sCD14 and sCD163, along with other laboratory parameters, and compared to a healthy control group.ResultssCD14 and sCD163 levels were significantly higher among COVID-19 patients, independently of ICU admission requirement, compared to the control group. We found a significant correlation between sCD14 levels and other inflammatory markers, particularly Interleukin-6, in the non-ICU patients group. sCD163 showed a moderate positive correlation with the time lapsed from admission to sampling, independently of severity group. Treatment with corticoids showed an interference with sCD14 levels, whereas hydroxychloroquine and tocilizumab did not.ConclusionsMonocyte-macrophage activation markers are increased and correlate with other inflammatory markers in SARS-Cov-2 infection, in association to hospital admission. These data suggest a preponderant role for monocyte-macrophage activation in the development of immunopathology of COVID-19 patients. |
| first_indexed | 2024-12-12T23:38:01Z |
| format | Article |
| id | doaj.art-5739cc9901d9452097fbf8cf217e69e6 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-12-12T23:38:01Z |
| publishDate | 2020-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-5739cc9901d9452097fbf8cf217e69e62022-12-22T00:07:19ZengFrontiers Media S.A.Frontiers in Immunology1664-32242020-09-011110.3389/fimmu.2020.560381560381Increased Serum Levels of sCD14 and sCD163 Indicate a Preponderant Role for Monocytes in COVID-19 ImmunopathologyJose Gómez-Rial0Jose Gómez-Rial1Maria José Currás-Tuala2Irene Rivero-Calle3Irene Rivero-Calle4Alberto Gómez-Carballa5Alberto Gómez-Carballa6Miriam Cebey-López7Carmen Rodríguez-Tenreiro8Ana Dacosta-Urbieta9Ana Dacosta-Urbieta10Carmen Rivero-Velasco11Nuria Rodríguez-Núñez12Rocio Trastoy-Pena13Javier Rodríguez-García14Antonio Salas15Antonio Salas16Federico Martinón-Torres17Federico Martinón-Torres18Grupo de Investigación en Genética, Vacunas, Infecciones y Pediatría, Instituto de Investigación Sanitaria de Santiago, Hospital Clinico Universitario and Universidade de Santiago de Compostela, Servizo Galego de Saúde, Galicia, SpainLaboratorio de Inmunologìa, Servicio de Análisis Clìnicos, Hospital Clìnico Universitario Santiago de Compostela, Servizo Galego de Saúde, Galicia, SpainGrupo de Investigación en Genética, Vacunas, Infecciones y Pediatría, Instituto de Investigación Sanitaria de Santiago, Hospital Clinico Universitario and Universidade de Santiago de Compostela, Servizo Galego de Saúde, Galicia, SpainGrupo de Investigación en Genética, Vacunas, Infecciones y Pediatría, Instituto de Investigación Sanitaria de Santiago, Hospital Clinico Universitario and Universidade de Santiago de Compostela, Servizo Galego de Saúde, Galicia, SpainTranslational Pediatrics and Infectious Diseases Section, Department of Pediatrics, Hospital Clìnico Universitario de Santiago de Compostela, Galicia, SpainGrupo de Investigación en Genética, Vacunas, Infecciones y Pediatría, Instituto de Investigación Sanitaria de Santiago, Hospital Clinico Universitario and Universidade de Santiago de Compostela, Servizo Galego de Saúde, Galicia, SpainUnidade de Xenética, Instituto de Ciencias Forenses, Facultade de Medicina, Universidade de Santiago de Compostela, and GenPoB Research Group, Instituto de Investigación Sanitaria (IDIS), Hospital Clìnico Universitario de Santiago, Servizo Galego de Saúde, Galicia, SpainGrupo de Investigación en Genética, Vacunas, Infecciones y Pediatría, Instituto de Investigación Sanitaria de Santiago, Hospital Clinico Universitario and Universidade de Santiago de Compostela, Servizo Galego de Saúde, Galicia, SpainGrupo de Investigación en Genética, Vacunas, Infecciones y Pediatría, Instituto de Investigación Sanitaria de Santiago, Hospital Clinico Universitario and Universidade de Santiago de Compostela, Servizo Galego de Saúde, Galicia, SpainGrupo de Investigación en Genética, Vacunas, Infecciones y Pediatría, Instituto de Investigación Sanitaria de Santiago, Hospital Clinico Universitario and Universidade de Santiago de Compostela, Servizo Galego de Saúde, Galicia, SpainTranslational Pediatrics and Infectious Diseases Section, Department of Pediatrics, Hospital Clìnico Universitario de Santiago de Compostela, Galicia, SpainIntensive Medicine Department, Hospital Clìnico Universitario de Santiago de Compostela, Galicia, SpainPneumology Department, Hospital Clìnico Universitario de Santiago de Compostela, Galicia, SpainMicrobiology Department, Hospital Clìnico Universitario de Santiago de Compostela, Galicia, SpainClinical Biochemistry Laboratory, Hospital Clìnico Universitario de Santiago de Compostela, Galicia, SpainGrupo de Investigación en Genética, Vacunas, Infecciones y Pediatría, Instituto de Investigación Sanitaria de Santiago, Hospital Clinico Universitario and Universidade de Santiago de Compostela, Servizo Galego de Saúde, Galicia, SpainUnidade de Xenética, Instituto de Ciencias Forenses, Facultade de Medicina, Universidade de Santiago de Compostela, and GenPoB Research Group, Instituto de Investigación Sanitaria (IDIS), Hospital Clìnico Universitario de Santiago, Servizo Galego de Saúde, Galicia, SpainGrupo de Investigación en Genética, Vacunas, Infecciones y Pediatría, Instituto de Investigación Sanitaria de Santiago, Hospital Clinico Universitario and Universidade de Santiago de Compostela, Servizo Galego de Saúde, Galicia, SpainTranslational Pediatrics and Infectious Diseases Section, Department of Pediatrics, Hospital Clìnico Universitario de Santiago de Compostela, Galicia, SpainBackgroundEmerging evidence indicates a potential role for monocytes in COVID-19 immunopathology. We investigated two soluble markers of monocyte activation, sCD14 and sCD163, in COVID-19 patients, with the aim of characterizing their potential role in monocyte-macrophage disease immunopathology. To the best of our knowledge, this is the first study of its kind.MethodsFifty-nine SARS-Cov-2 positive hospitalized patients, classified according to ICU or non-ICU admission requirement, were prospectively recruited and analyzed by ELISA for levels of sCD14 and sCD163, along with other laboratory parameters, and compared to a healthy control group.ResultssCD14 and sCD163 levels were significantly higher among COVID-19 patients, independently of ICU admission requirement, compared to the control group. We found a significant correlation between sCD14 levels and other inflammatory markers, particularly Interleukin-6, in the non-ICU patients group. sCD163 showed a moderate positive correlation with the time lapsed from admission to sampling, independently of severity group. Treatment with corticoids showed an interference with sCD14 levels, whereas hydroxychloroquine and tocilizumab did not.ConclusionsMonocyte-macrophage activation markers are increased and correlate with other inflammatory markers in SARS-Cov-2 infection, in association to hospital admission. These data suggest a preponderant role for monocyte-macrophage activation in the development of immunopathology of COVID-19 patients.https://www.frontiersin.org/article/10.3389/fimmu.2020.560381/fullCOVID-19monocytesCD14sCD163immunopathology |
| spellingShingle | Jose Gómez-Rial Jose Gómez-Rial Maria José Currás-Tuala Irene Rivero-Calle Irene Rivero-Calle Alberto Gómez-Carballa Alberto Gómez-Carballa Miriam Cebey-López Carmen Rodríguez-Tenreiro Ana Dacosta-Urbieta Ana Dacosta-Urbieta Carmen Rivero-Velasco Nuria Rodríguez-Núñez Rocio Trastoy-Pena Javier Rodríguez-García Antonio Salas Antonio Salas Federico Martinón-Torres Federico Martinón-Torres Increased Serum Levels of sCD14 and sCD163 Indicate a Preponderant Role for Monocytes in COVID-19 Immunopathology Frontiers in Immunology COVID-19 monocyte sCD14 sCD163 immunopathology |
| title | Increased Serum Levels of sCD14 and sCD163 Indicate a Preponderant Role for Monocytes in COVID-19 Immunopathology |
| title_full | Increased Serum Levels of sCD14 and sCD163 Indicate a Preponderant Role for Monocytes in COVID-19 Immunopathology |
| title_fullStr | Increased Serum Levels of sCD14 and sCD163 Indicate a Preponderant Role for Monocytes in COVID-19 Immunopathology |
| title_full_unstemmed | Increased Serum Levels of sCD14 and sCD163 Indicate a Preponderant Role for Monocytes in COVID-19 Immunopathology |
| title_short | Increased Serum Levels of sCD14 and sCD163 Indicate a Preponderant Role for Monocytes in COVID-19 Immunopathology |
| title_sort | increased serum levels of scd14 and scd163 indicate a preponderant role for monocytes in covid 19 immunopathology |
| topic | COVID-19 monocyte sCD14 sCD163 immunopathology |
| url | https://www.frontiersin.org/article/10.3389/fimmu.2020.560381/full |
| work_keys_str_mv | AT josegomezrial increasedserumlevelsofscd14andscd163indicateapreponderantroleformonocytesincovid19immunopathology AT josegomezrial increasedserumlevelsofscd14andscd163indicateapreponderantroleformonocytesincovid19immunopathology AT mariajosecurrastuala increasedserumlevelsofscd14andscd163indicateapreponderantroleformonocytesincovid19immunopathology AT ireneriverocalle increasedserumlevelsofscd14andscd163indicateapreponderantroleformonocytesincovid19immunopathology AT ireneriverocalle increasedserumlevelsofscd14andscd163indicateapreponderantroleformonocytesincovid19immunopathology AT albertogomezcarballa increasedserumlevelsofscd14andscd163indicateapreponderantroleformonocytesincovid19immunopathology AT albertogomezcarballa increasedserumlevelsofscd14andscd163indicateapreponderantroleformonocytesincovid19immunopathology AT miriamcebeylopez increasedserumlevelsofscd14andscd163indicateapreponderantroleformonocytesincovid19immunopathology AT carmenrodrigueztenreiro increasedserumlevelsofscd14andscd163indicateapreponderantroleformonocytesincovid19immunopathology AT anadacostaurbieta increasedserumlevelsofscd14andscd163indicateapreponderantroleformonocytesincovid19immunopathology AT anadacostaurbieta increasedserumlevelsofscd14andscd163indicateapreponderantroleformonocytesincovid19immunopathology AT carmenriverovelasco increasedserumlevelsofscd14andscd163indicateapreponderantroleformonocytesincovid19immunopathology AT nuriarodrigueznunez increasedserumlevelsofscd14andscd163indicateapreponderantroleformonocytesincovid19immunopathology AT rociotrastoypena increasedserumlevelsofscd14andscd163indicateapreponderantroleformonocytesincovid19immunopathology AT javierrodriguezgarcia increasedserumlevelsofscd14andscd163indicateapreponderantroleformonocytesincovid19immunopathology AT antoniosalas increasedserumlevelsofscd14andscd163indicateapreponderantroleformonocytesincovid19immunopathology AT antoniosalas increasedserumlevelsofscd14andscd163indicateapreponderantroleformonocytesincovid19immunopathology AT federicomartinontorres increasedserumlevelsofscd14andscd163indicateapreponderantroleformonocytesincovid19immunopathology AT federicomartinontorres increasedserumlevelsofscd14andscd163indicateapreponderantroleformonocytesincovid19immunopathology |